1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pain Management Therapeutics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Therapeutics Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Pain Management Therapeutics Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
    4.5. Porter’s Five Force Analysis
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Mergers & Acquisitions
    5.3. Covid 19 Impact Analysis
6. Global Pain Management Therapeutics Market Analysis and Forecast, by Therapeutic
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Therapeutic, 2017–2031
        6.3.1. Anticonvulsants
        6.3.2. Antidepressants
        6.3.3. Anesthetics
        6.3.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        6.3.5. Opioids
        6.3.6. Other Non-narcotic Analgesic
        6.3.7. Antimigraine Agents
    6.4. Market Attractiveness Analysis, by Therapeutic
7. Global Pain Management Therapeutics Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Indication, 2017–2031
        7.3.1. Neuropathic Pain
        7.3.2. Fibromyalgia
        7.3.3. Arthritic Pain
        7.3.4. Chronic Back Pain
        7.3.5. Migraine
        7.3.6. Post-operative Pain
        7.3.7. Cancer Pain
    7.4. Market Attractiveness Analysis, by Indication
8. Global Pain Management Therapeutics Market Analysis and Forecast, by Route of Administration
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Route of Administration, 2017–2031
        8.3.1. Oral
        8.3.2. Parenteral
        8.3.3. Others
    8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Pain Management Therapeutics Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017–2031
        9.3.1. Retail Pharmacies
        9.3.2. Online Pharmacies
        9.3.3. Others
    9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Pain Management Therapeutics Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Pain Management Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Therapeutic, 2017–2031
        11.2.1. Anticonvulsants
        11.2.2. Antidepressants
        11.2.3. Anesthetics
        11.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        11.2.5. Opioids
        11.2.6. Other Non-narcotic Analgesic
        11.2.7. Antimigraine Agents
    11.3. Market Value Forecast, by Indication, 2017–2031
        11.3.1. Neuropathic Pain
        11.3.2. Fibromyalgia
        11.3.3. Arthritic Pain
        11.3.4. Chronic Back Pain
        11.3.5. Migraine
        11.3.6. Post-operative Pain
        11.3.7. Cancer Pain
    11.4. Market Value Forecast, by Route of Administration, 2017–2031
        11.4.1. Oral
        11.4.2. Parenteral
        11.4.3. Others
    11.5. Market Value Forecast, by Distribution Channel, 2017–2031
        11.5.1. Retail Pharmacies
        11.5.2. Online Pharmacies
        11.5.3. Others
    11.6. Market Value Forecast, by Country, 2017–2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Therapeutic
        11.7.2. By Indication
        11.7.3. By Route of Administration
        11.7.4. By Distribution Channel
        11.7.5. By Country
12. Europe Pain Management Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Therapeutic, 2017–2031
        12.2.1. Anticonvulsants
        12.2.2. Antidepressants
        12.2.3. Anesthetics
        12.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        12.2.5. Opioids
        12.2.6. Other Non-narcotic Analgesic
        12.2.7. Antimigraine Agents
    12.3. Market Value Forecast, by Indication, 2017–2031
        12.3.1. Neuropathic Pain
        12.3.2. Fibromyalgia
        12.3.3. Arthritic Pain
        12.3.4. Chronic Back Pain
        12.3.5. Migraine
        12.3.6. Post-operative Pain
        12.3.7. Cancer Pain
    12.4. Market Value Forecast, by Route of Administration, 2017–2031
        12.4.1. Oral
        12.4.2. Parenteral
        12.4.3. Others
    12.5. Market Value Forecast, by Distribution Channel, 2017–2031
        12.5.1. Retail Pharmacies
        12.5.2. Online Pharmacies
        12.5.3. Others
    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Spain
        12.6.5. Italy
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Therapeutic
        12.7.2. By Indication
        12.7.3. By Route of Administration
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region
13. Asia Pacific Pain Management Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Therapeutic, 2017–2031
        13.2.1. Anticonvulsants
        13.2.2. Antidepressants
        13.2.3. Anesthetics
        13.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        13.2.5. Opioids
        13.2.6. Other Non-narcotic Analgesic
        13.2.7. Antimigraine Agents
    13.3. Market Value Forecast, by Indication, 2017–2031
        13.3.1. Neuropathic Pain
        13.3.2. Fibromyalgia
        13.3.3. Arthritic Pain
        13.3.4. Chronic Back Pain
        13.3.5. Migraine
        13.3.6. Post-operative Pain
        13.3.7. Cancer Pain
    13.4. Market Value Forecast, by Route of Administration, 2017–2031
        13.4.1. Oral
        13.4.2. Parenteral
        13.4.3. Others
    13.5. Market Value Forecast, by Distribution Channel, 2017–2031
        13.5.1. Retail Pharmacies
        13.5.2. Online Pharmacies
        13.5.3. Others
    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Therapeutic
        13.7.2. By Indication
        13.7.3. By Route of Administration
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region
14. Latin America Pain Management Therapeutics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Therapeutic, 2017–2031
        14.2.1. Anticonvulsants
        14.2.2. Antidepressants
        14.2.3. Anesthetics
        14.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        14.2.5. Opioids
        14.2.6. Other Non-narcotic Analgesic
        14.2.7. Antimigraine Agents
    14.3. Market Value Forecast, by Indication, 2017–2031
        14.3.1. Neuropathic Pain
        14.3.2. Fibromyalgia
        14.3.3. Arthritic Pain
        14.3.4. Chronic Back Pain
        14.3.5. Migraine
        14.3.6. Post-operative Pain
        14.3.7. Cancer Pain
    14.4. Market Value Forecast, by Route of Administration, 2017–2031
        14.4.1. Oral
        14.4.2. Parenteral
        14.4.3. Others
    14.5. Market Value Forecast, by Distribution Channel, 2017–2031
        14.5.1. Retail Pharmacies
        14.5.2. Online Pharmacies
        14.5.3. Others
    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Therapeutic
        14.7.2. By Indication
        14.7.3. By Route of Administration
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region
15. Middle East & Africa Pain Management Therapeutics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Therapeutic, 2017–2031
        15.2.1. Anticonvulsants
        15.2.2. Antidepressants
        15.2.3. Anesthetics
        15.2.4. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
        15.2.5. Opioids
        15.2.6. Other Non-narcotic Analgesic
        15.2.7. Antimigraine Agents
    15.3. Market Value Forecast, by Indication, 2017–2031
        15.3.1. Neuropathic Pain
        15.3.2. Fibromyalgia
        15.3.3. Arthritic Pain
        15.3.4. Chronic Back Pain
        15.3.5. Migraine
        15.3.6. Post-operative Pain
        15.3.7. Cancer Pain
    15.4. Market Value Forecast, by Route of Administration, 2017–2031
        15.4.1. Oral
        15.4.2. Parenteral
        15.4.3. Others
    15.5. Market Value Forecast, by Distribution Channel, 2017–2031
        15.5.1. Retail Pharmacies
        15.5.2. Online Pharmacies
        15.5.3. Others
    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Therapeutic
        15.7.2. By Indication
        15.7.3. By Route of Administration
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company, 2021
    16.3. Company Profiles
        16.3.1. Abbott Laboratories
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Financial Analysis
            16.3.1.3. Growth Strategies
            16.3.1.4. SWOT Analysis
        16.3.2. AstraZeneca plc
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Financial Analysis
            16.3.2.3. Growth Strategies
            16.3.2.4. SWOT Analysis
        16.3.3. Pfizer, Inc.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Financial Analysis
            16.3.3.3. Growth Strategies
            16.3.3.4. SWOT Analysis
        16.3.4. Depomed, Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Financial Analysis
            16.3.4.3. Growth Strategies
            16.3.4.4. SWOT Analysis
        16.3.5. Endo International plc
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Financial Analysis
            16.3.5.3. Growth Strategies
            16.3.5.4. SWOT Analysis
        16.3.6. GlaxoSmithKline plc
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Financial Analysis
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			